Avvio Medical Proudly Announces ISO 13485 Certification, Marking a Major Milestone in Global MedTech Readiness

Audio By Carbonatix

SAN FRANCISCO--(BUSINESS WIRE)--Jun 25, 2025--

Avvio Medical, Inc., a clinical-stage medical device company focused on transforming the treatment of kidney stone disease, is proud to announce that it has successfully achieved ISO 13485:2016 certification following its initial audit conducted by BSI (British Standards Institution). This globally recognized certification demonstrates Avvio’s compliance with international standards for medical device quality management systems and reflects the company’s unwavering commitment to excellence, patient safety, and operational rigor.

“This milestone is more than a regulatory requirement—it represents the fulfillment of our promise to stand up a full-scale medical device company,” said Paul Molloy, CEO of Avvio Medical. “Through disciplined execution, a culture of continuous improvement, and a mindset grounded in honor, behavioral integrity, and precision, we have built a foundation for scalable, global operations.” He added, “The quality culture at Avvio is not just a box-checking exercise. We embed it through storytelling, structured messaging, and principles drawn from disciplines of Lean and KAIZEN and a culture Bushidō. As we shared with the BSI audit team, our internal motto is #ImproveEverything—and this certification illustrates that we live by it.”

The ISO 13485 certification now enables Avvio to fully qualify its manufacturing and design processes for commercial scaling, pursue CE marking for international distribution, and reinforce confidence among global partners, investors, and regulators. The achievement is a major step toward the company’s upcoming 2026 commercial launch in the U.S. market. With this certification, Avvio affirms that it is not only compliant—but built to lead.

About the Enhanced Lithotripsy System (ELS)

The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers.

About Avvio Medical

Avvio Medical is a privately held medical technology company based in San Francisco and dedicated to transforming the treatment of urinary stones. Its breakthrough platform is designed to improve patient experience, reduce healthcare costs, and expand access to care by offering a fast, minimally invasive solution suitable for a wide range of clinical settings. The company’s system eliminates the routine need for general anesthesia or X-ray imaging, streamlining the treatment pathway for both patients and healthcare professionals.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250625553966/en/

CONTACT: Media Contact:

Paul Molloy

Chief Executive Officer

Avvio Medical, Inc.

Email:[email protected]

Tel: (415) 887-2037

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PRACTICE MANAGEMENT SURGERY GENERAL HEALTH HEALTH MEDICAL DEVICES HOSPITALS HEALTH TECHNOLOGY

SOURCE: Avvio Medical, Inc.

Copyright Business Wire 2025.

PUB: 06/25/2025 08:28 PM/DISC: 06/25/2025 08:27 PM

http://www.businesswire.com/news/home/20250625553966/en